Last reviewed · How we verify
Dexamethasone, Rituximab, Cyclophosphamide
This combination regimen suppresses B-cell mediated autoimmunity by depleting CD20+ B cells with rituximab while cyclophosphamide provides cytotoxic immunosuppression and dexamethasone provides corticosteroid anti-inflammatory effects.
This combination regimen suppresses B-cell mediated autoimmunity by depleting CD20+ B cells with rituximab while cyclophosphamide provides cytotoxic immunosuppression and dexamethasone provides corticosteroid anti-inflammatory effects. Used for Autoimmune diseases (likely systemic lupus erythematosus, vasculitis, or other B-cell mediated autoimmune conditions).
At a glance
| Generic name | Dexamethasone, Rituximab, Cyclophosphamide |
|---|---|
| Sponsor | University of Ulm |
| Drug class | Monoclonal antibody + alkylating agent + corticosteroid combination |
| Target | CD20 (rituximab); DNA (cyclophosphamide); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a chimeric monoclonal antibody that binds CD20 on B-cell surfaces, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Cyclophosphamide is an alkylating agent that causes DNA cross-linking and broad immunosuppression. Dexamethasone is a glucocorticoid that suppresses inflammatory cytokine production and T-cell activation. Together, this combination targets multiple pathways of adaptive immunity.
Approved indications
- Autoimmune diseases (likely systemic lupus erythematosus, vasculitis, or other B-cell mediated autoimmune conditions)
Common side effects
- Infection (bacterial, viral, opportunistic)
- Myelosuppression / cytopenias
- Infusion reactions
- Hyperglycemia
- Immunosuppression-related complications
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- BNHL-2015 for Children or Adolescents in China (PHASE2, PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |